Roth boosts Peloton target to $66, says buy Mirror acquisition selloff
Roth Capital analyst George Kelly raised the firm's price target on Peloton Interactive (PTON) to $66 from $51 and keeps a Buy rating on the...
Author : The Fly
Uber in talks to acquire Postmates for about $2.6B, WSJ reports
Uber Technologies (UBER) is in discussions to buy Postmates for about $2.6B, Cara Lombardo of Wall Street Journal reports, citing people familiar with the matter....
Fly Intel: Wall Street’s top stories for Monday
Stocks saw a rebound from last week's downbeat trading after an index of pending home sales notched a record gain. Investors may also... To see...
Facebook acknowledges ‘much more work to do’ on keeping platform safe
Facebook said in a statement, "We recognize our responsibility to facilitate a safe environment for everyone using our platforms. To do this, we have to...
Planet Fitness drops after West Virginia county asks clients to quarantine
Shares of Planet Fitness are lower after West Virginia's Monongalia County Health Department announced over the weekend that a client of the fitness center tested...
Fly Insider: Epizyme,DraftKings among week’s notable insider transactions
Welcome to "Fly Insider," The Fly's weekly recap of notable insider stock transactions. NOTABLE INSIDER PURCHASES:... To see the rest of the story go to...
Fly Intel: What to watch in Micron’s earnings report
Micron (MU) is scheduled to report results of its fiscal third quarter after the market close on June 29, with a conference call scheduled for...
Fly Intel: Wall Street’s top stories at midday
Stocks are rising in a rebound from last week's downbeat trading after an index of pending home sales notched a record gain. Investors may also......
Sonos shares heading to $30 on ‘booming’ demand, Citron says
Andrew Left's Citron Research reiterated its belief that shares of Sonos are going to $30. The stock in midday trading is down 32c to $14.69....
Kiniksa price target raised to $38 from $30 at Wedbush
Wedbush analyst David Nierengarten raised the firm's price target on Kiniksa Pharmaceuticals to $38 from $30 and reiterates an Outperform rating on the shares. The...